Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30883 | 0.84 | AOC3 (0.55) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL7630871 | 0.83 | AOC3 (0.53) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL8910900 | 0.82 | AOC3 (0.56) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL95872 | 0.81 | CA12 (0.53) | SMN1; SMN2POLBCYP1A2KDM4ETSHR | |
| SCHEMBL23931092 | 0.78 | AOC3 (0.53) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL775238 | 0.78 | AOC3 (0.53) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL2338539 | 0.78 | AOC3 (0.53) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL3237585 | 0.78 | AOC3 (0.53) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL6212313 | 0.78 | AOC3 (0.53) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL4678057 | 0.78 | AOC3 (0.53) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3187838-B2 | — | — | 2001-07-16 | — | — | JP | claimed |
| EP-0737195-A1 | NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1996-10-16 | — | — | EP | claimed |
| US-5541183-A | RESPIRATORY SYSTEM DISORDERS, SKIN DISORDERS AND PLATELET ACTIVATING FACTOR ANTAGONIST | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1996-07-30 | — | — | US | claimed |
| WO-1995018131-A1 | NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1995-07-06 | — | — | WO | claimed |
| US-20090036659-A1 | METHOD OF DEUTERATING BENZYL-POSITION IN -O-BENZYL GROUP | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1992605-A1 | METHOD OF DEUTERIZING BENZYL-POSITION IN -O-BENZYL GROUP | Wako Pure Chemical Industries, Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-7390926-B2 | Process for the diastereoselective alkylation of an ether oxime of the compound nopinone and novel intermediates for the synthesis of diastereospecific 2-amino-nopinone derivatives substituted on carbon 3 | ZACH SYSTEM (IT) | 2008-06-24 | — | — | US | disclosed |
| US-20070225516-A1 | Process for the diastereoselective alkylation of an ether oxime of the compound nopinone and novel intermediates for the synthesis of diastereospecific 2-amino-nopinone derivatives substituted on carbon 3 | PPG-SIPSY (FR) | 2007-09-27 | — | — | US | disclosed |
| US-7247714-B2 | Protection against oxidative stress and inflammation by a cytoprotective response element | ATHEROGENICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | MENG CHARLES Q | 2006-11-16 | — | — | US | disclosed |
| US-7078431-B2 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | disclosed |
| US-4537720-A | N-substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamino)-4-oxo-azetidines and process | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| US-4477660-A | 7-(S)-Acylaminocephalosporin sulfones and process | ELI LILLY AND COMPANY (US) | 1984-10-16 | — | — | US | disclosed |
| US-4474879-A | Process for 3-hydroxymethyl cephalosporin sulfones | ELI LILLY AND COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| US-4459405-A | Desacetylcephalosporin sulfones | ELI LILLY AND COMPANY (US) | 1984-07-10 | — | — | US | disclosed |
| EP-0109816-A1 | N-substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamido)-4-oxo-azetidines and process | ELI LILLY AND COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
| EP-0109301-A2 | 7-(S)-acylaminocephalosporin sulfones and process | ELI LILLY AND COMPANY (US) | 1984-05-23 | — | — | EP | disclosed |
| EP-0109300-A2 | Desacetylcephalosporin sulfones | ELI LILLY AND COMPANY (US) | 1984-05-23 | — | — | EP | disclosed |
| US-4436596-A | N-Substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamido)-4-oxo-azetidines and process | ELI LILLY AND COMPANY (US) | 1984-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225516-A1 | Process for the diastereoselective alkylation of an ether oxime of the compound nopinone and novel intermediates for the synthesis of diastereospecific 2-amino-nopinone derivatives substituted on carbon 3 | NOP2, NOP10, NOP56 | AOC3 105/4885SMN1; SMN2 1770/4885POLB 2716/4885 |
| US-20090036659-A1 | METHOD OF DEUTERATING BENZYL-POSITION IN -O-BENZYL GROUP | DBH, BRD4, BRD3 | AOC3 185/4885SMN1; SMN2 3340/4885POLB 203/4885 |
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | AOC3 1968/4885SMN1; SMN2 2256/4885POLB 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.